Literature DB >> 15715087

Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.

Trude Holmeide Agesen1, Vivi Ann Flørenes, Willemina M Molenaar, Guro E Lind, Jeanne-Marie Berner, Boudewijn E C Plaat, Rudy Komdeur, Ola Myklebost, Eva van den Berg, Ragnhild A Lothe.   

Abstract

The molecular biology underlying the development of highly malignant peripheral nerve sheath tumors (MPNSTs) remains mostly unknown. In the present study, the expression pattern of 10 selected cell cycle components is investigated in a series of 15 MPNSTs from patients with (n = 9) or without (n = 5) neurofibromatosis type 1 (NF1). Thirteen tumors did not express the cyclin-dependent kinase inhibitor, p16(INK4A), an observation that was related to homozygote gene deletions in three tumors, heterozygote deletions in five, and gross gene rearrangements in five. The absence of protein expression in the tumors with one seemingly intact allele was not caused by promoter hypermethylation of p16(INK4A) or p14(ARF). All tumor samples expressed normal sized RB1, cyclin D3, CDK2, CDK4, p21(CIP1), and p27(KlP1) proteins, and only a single tumor showed an aberrant protein band for one of these proteins, p21(CIP1). Cyclin D1 was absent in four tumors; all except one tumor showed expression of TP53 protein, and three of nine MPNSTs had expression of normal-sized MDM2. In conclusion, this study shows that the vast majority of MPNSTs had gross rearrangements of the p16(INK4A) gene, explaining the absence of the encoded protein in the same tumors. The level of expression was equally distributed between the familial (NF1) and sporadic cases, although it should be noted that the 2 cases with p16(INK4A) expression were sporadic. The data imply that the complete absence of p16(INK4A) is sufficient for activation of the cell cycle in most MPNSTs; thus, it is not necessary for tumor proliferation to further stimulate the cycle through alteration of other central components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715087     DOI: 10.1093/jnen/64.1.74

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  14 in total

1.  Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.

Authors:  Christian Hagel; Ulrich Zils; Matthias Peiper; Lan Kluwe; Stefan Gotthard; Reinhard E Friedrich; David Zurakowski; Andreas von Deimling; Victor Felix Mautner
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.130

Review 2.  Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Authors:  Nicole M Brossier; Steven L Carroll
Journal:  Brain Res Bull       Date:  2011-08-10       Impact factor: 4.077

3.  CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration.

Authors:  Nicole D Riddle; Lemuel Gorden; Mumtaz V Rojiani; Ardeshir Hakam; Amyn M Rojiani
Journal:  Int J Clin Exp Pathol       Date:  2010-06-12

4.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

5.  Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.

Authors:  Helge R Brekke; Matthias Kolberg; Rolf I Skotheim; Kirsten S Hall; Bodil Bjerkehagen; Björn Risberg; Henryk A Domanski; Nils Mandahl; Knut Liestøl; Sigbjørn Smeland; Håvard E Danielsen; Fredrik Mertens; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2009-01-30       Impact factor: 12.300

6.  The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.

Authors:  Nancy M Joseph; Jack T Mosher; Johanna Buchstaller; Paige Snider; Paul E McKeever; Megan Lim; Simon J Conway; Luis F Parada; Yuan Zhu; Sean J Morrison
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

7.  Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions.

Authors:  Johanna Buchstaller; Paul E McKeever; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

Review 8.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

9.  CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells.

Authors:  Grace Wing-Yan Mak; Wai-Lung Lai; Yuan Zhou; Mingtao Li; Irene Oi-Lin Ng; Yick-Pang Ching
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.

Authors:  Stine A Danielsen; Guro E Lind; Matthias Kolberg; Maren Høland; Bodil Bjerkehagen; Kirsten Sundby Hall; Eva van den Berg; Fredrik Mertens; Sigbjørn Smeland; Piero Picci; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2014-07-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.